- Home
- LPX vs WGS Comparison
LPX vs WGS Comparison
Compare LPX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPX | WGS |
|---|---|---|
| Founded | 1973 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Retail: Computer Software & Peripheral Equipment |
| Sector | Basic Materials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LPX | WGS |
|---|---|---|
| Price | $85.19 | $135.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $109.14 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 931.3K | 397.0K |
| Earning Date | 02-18-2026 | 02-17-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.02 | 0.07 |
| Revenue | ★ $2,821,000,000.00 | $402,190,000.00 |
| Revenue This Year | N/A | $41.17 |
| Revenue Next Year | $5.89 | $23.53 |
| P/E Ratio | ★ $27.77 | $1,788.17 |
| Revenue Growth | N/A | ★ 50.50 |
| 52 Week Low | $73.42 | $55.17 |
| 52 Week High | $119.91 | $170.87 |
Technical Indicators
Market Signals| Indicator | LPX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 44.60 |
| Support Level | $79.56 | $124.26 |
| Resistance Level | $83.16 | $139.00 |
| Average True Range (ATR) | 2.02 | 6.76 |
| MACD | 0.05 | -1.10 |
| Stochastic Oscillator | 82.73 | 42.77 |
Price Performance
Historical ComparisonAbout LPX Louisiana-Pacific Corporation
Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.